1cg,FdwemeE 71 r DC gicaltreatmen 72 sei业ma V.Brito IP.WangZ Prokop L den AG.Sto Dl.We 83 Zhyzhn alts from d20162676 Graves'dis 96 n AH. D the ma nagement of thyr Santos RB ese per Burch HB Warto Mc Biondi B.Bar 695-70 M:a opea 26617 A..Chr O:K.Ka sof ntth 79 A.Lube AB.Khat d dwit rm.Clin E tTtnot2016.84912-gh t to the ca be enign thy dise a 01 80 sd and n ced by en Wp. AB Khaw ective, 102 Crc2ton2012z126:1040-1049 2017102-2301-2309 Kahaly/Bartalena/Hegeduis/Leenhardt/ Poppe/Pearce 医通 http://guide.medlive.cn/ Kahaly/Bartalena/Hegedüs/Leenhardt/ Poppe/Pearce 184 Eur Thyroid J 2018;7:167–186 DOI: 10.1159/000490384 70 Rivkees SA, Mattison DR: Ending propylthio￾uracil-induced liver failure in children. N Engl J Med 2009;360:1574–1575. 71 Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH: Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population￾based cohort study. Br J Clin Pharmacol 2014; 78:619–629. 72 Castro MR, Espiritu RP, Bahn RS, Henry MR, Gharib H, Caraballo PJ, Morris JC: Predictors of malignancy in patients with cytologically suspicious thyroid nodules. Thyroid 2011;21: 1191–1198. 73 Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS: Comparative effectiveness of therapies for Graves’ hyper￾thyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2013; 98:3671–3677. 74 Struja T, Fehlberg H, Kutz A, Guebelin L, De￾gen C, Mueller B, Schuetz P: Can we predict relapse in Graves’ disease? Results from a sys￾tematic review and meta-analysis. Eur J En￾docrinol 2017;176:87–97. 75 Vos XG, Endert E, Zwinderman AH, Tijssen JG, Wiersinga WM: Predicting the risk of re￾currence before the start of antithyroid drug therapy in patients with Graves’ hyperthy￾roidism. J Clin Endocrinol Metab 2016;101: 1381–1389. 76 Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS: Outcomes in relapsed Graves’ disease patients following radioio￾dine or prolonged low dose of methimazole treatment. Thyroid 2015;25:1282–1290. 77 Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F: Effect of long-term contin￾uous methimazole treatment of hyperthy￾roidism: comparison with radioiodine. Eur J Endocrinol 2005;152:695–701. 78 Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Kahaly GJ: The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hy￾perthyroidism. Eur Thyroid J 2015;4:149– 163. 79 Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Asvold BO, Sgarbi JA, Volzke H, Gencer B, Maciel RM, Molinaro S, Bremner A, Luben RN, Mai￾sonneuve P, Cornuz J, Newman AB, Khaw KT, Westendorp RG, Franklyn JA, Vitting￾hoff E, Walsh JP, Rodondi N; Thyroid Studies Collaboration: Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012;172:799– 809. 80 Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, Nanchen D, den El￾zen WP, Balmer P, Luben RN, Iacoviello M, Triggiani V, Cornuz J, Newman AB, Khaw KT, Jukema JW, Westendorp RG, Vittinghoff E, Aujesky D, Rodondi N; Thyroid Studies Col￾laboration: Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective co￾horts. Circulation 2012;126:1040–1049. 81 Wirth CD, Blum MR, da Costa BR, Baumgart￾ner C, Collet TH, Medici M, Peeters RP, Aujesky D, Bauer DC, Rodondi N: Subclinical thyroid dysfunction and the risk for fractures: a systematic review and meta-analysis. Ann Intern Med 2014;161:189–199. 82 Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Asvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlin￾den AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Wil￾liams GR, Walsh JP, Juni P, Aujesky D, Rodondi N; Thyroid Studies Collaboration: Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 2015;313:2055– 2065. 83 Zhyzhneuskaya S, Addison C, Tsatlidis V, Weaver JU, Razvi S: The natural history of subclinical hyperthyroidism in Graves’ dis￾ease: the rule of thirds. Thyroid 2016;26:765– 769. 84 Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, Kanamoto N, Otani H, Furuka￾wa Y, Teramukai S, Akamizu T: 2016 guide￾lines for the management of thyroid storm from the Japan Thyroid Association and Ja￾pan Endocrine Society (first edition). Endocr J 2016;63:1025–1064. 85 Akamizu T: Thyroid storm: a Japanese per￾spective. Thyroid 2018;28:32–40. 86 Burch HB, Wartofsky L: Life-threatening thy￾rotoxicosis: thyroid storm. Endocrinol Metab Clin North Am 1993;22:263–277. 87 Akamizu T, Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, Monden T, Kouki T, Otani H, Teramukai S, Uehara R, Nakamura Y, Nagai M, Mori M; Japan Thy￾roid Association: Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid 2012; 22:661–679. 88 Isozaki O, Satoh T, Wakino S, Suzuki A, Iburi T, Tsuboi K, Kanamoto N, Otani H, Furukawa Y, Teramukai S, Akamizu T: Treatment and management of thyroid storm: analysis of the nationwide surveys: the taskforce committee of the Japan Thyroid Association and Japan En￾docrine Society for the establishment of diag￾nostic criteria and nationwide surveys for thy￾roid storm. Clin Endocrinol 2016;84:912–918. 89 Bonnema SJ, Hegedus L: Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 2012;33:920–980. 90 Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Saaf M, Hamberger B: Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine – a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996; 81:2986–2993. 91 In H, Pearce EN, Wong AK, Burgess JF, McAneny DB, Rosen JE: Treatment options for Graves disease: a cost-effectiveness anal￾ysis. J Am Coll Surg 2009;209:170–179.e2. 92 Zanocco K, Heller M, Elaraj D, Sturgeon C: Is subtotal thyroidectomy a cost-effective treat￾ment for Graves disease? A cost-effectiveness analysis of the medical and surgical treatment options. Surgery 2012;152:164–172. 93 Patel NN, Abraham P, Buscombe J, Vander￾pump MP: The cost effectiveness of treat￾ment modalities for thyrotoxicosis in a UK center. Thyroid 2006;16:593–598. 94 Donovan PJ, McLeod DS, Little R, Gordon L: Cost-utility analysis comparing radioac￾tive iodine, anti-thyroid drugs and total thy￾roidectomy for primary treatment of Graves’ disease. Eur J Endocrinol 2016;175:595–603. 95 Cohen RZ, Felner EI, Heiss KF, Wyly JB, Muir AB: Outcomes analysis of radioactive iodine and total thyroidectomy for pediatric Graves’ disease. J Pediatr Endocrinol Metab 2016;29:319–325. 96 Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, Straus S, Thabane L, Gafni A, Ezzat S, George SR, Goldstein DP: A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol 2008;69:479–490. 97 Nygaard B, Hegedus L, Gervil M, Hjalgrim H, Hansen BM, Soe-Jensen P, Hansen JM: Influence of compensated radioiodine ther￾apy on thyroid volume and incidence of hy￾pothyroidism in Graves’ disease. J Intern Med 1995;238:491–497. 98 Sridama V, McCormick M, Kaplan EL, Fau￾chet R, DeGroot LJ: Long-term follow-up study of compensated low-dose 131I therapy for Graves’ disease. N Engl J Med 1984;311: 426–432. 99 Walter MA, Briel M, Christ-Crain M, Bonne￾ma SJ, Connell J, Cooper DS, Bucher HC, Muller-Brand J, Muller B: Effects of antithy￾roid drugs on radioiodine treatment: system￾atic review and meta-analysis of randomised controlled trials. BMJ 2007;334:514. 100 Brandt F, Thvilum M, Almind D, Chris￾tensen K, Green A, Hegedus L, Brix TH: Graves’ disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. Thyroid 2013;23:408–413. 101 Schwensen CF, Brandt F, Hegedus L, Brix TH: Mortality in Graves’ orbitopathy is in￾creased and influenced by gender, age and pre-existing morbidity: a nationwide Danish register study. Eur J Endocrinol 2017;176: 669–676. 102 Lillevang-Johansen M, Abrahamsen B, Jor￾gensen HL, Brix TH, Hegedus L: Excess mortality in treated and untreated hyperthy￾roidism is related to cumulative periods of low serum TSH. J Clin Endocrinol Metab 2017;102:2301–2309. http://guide.medlive.cn/